Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rituximab + gemcitabine + oxaliplatin + bendamustine + polatuzumab vedotin
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This is an investigational multi-agent chemotherapy and immunotherapy regimen combining five drugs: rituximab (a monoclonal antibody targeting CD20), gemcitabine (a nucleoside analog antimetabolite), oxaliplatin (a platinum-based chemotherapeutic), bendamustine (an alkylating agent with purine analog properties), and polatuzumab vedotin (an antibody-drug conjugate targeting CD79b). The combination is being studied primarily for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in patients who are not eligible for stem cell transplant. Rituximab depletes B-cells by binding to CD20, while polatuzumab vedotin delivers a cytotoxic agent to cells expressing CD79b, leading to apoptosis. Gemcitabine inhibits DNA synthesis, oxaliplatin causes DNA crosslinking and damage, and bendamustine induces cell death through alkylation of DNA. This combination aims to improve outcomes in heavily pretreated DLBCL patients by leveraging multiple mechanisms of action[2][8].
- Other names
- rituximab + gemcitabine + oxaliplatin + bendamustine + polatuzumab vedotin
02
Targets
CD20 (B-lymphocyte antigen CD20)RNR (Ribonucleotide reductase)B-cell antigen receptor complex-associated protein beta chainDNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on rituximab + gemcitabine + oxaliplatin + bendamustine + polatuzumab vedotin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rituximab + gemcitabine + oxaliplatin + bendamustine + polatuzumab vedotin.